Global Autism Spectrum Disorder Therapeutics Market Size, by Treatment (Medication, Therapy), by Age Group (Children, Adult) & Region - Key Manufacturers, Analysis, Growth Trends, and Forecast till 2026

  • Category : Healthcare and Pharma
  • |
  • ID : 1139773
  • |
  • Publishe Date : July-2019
  • |
  • No of Pages: 121
  • |
  • Publisher : Intellectual Research Partners

The Global Autism Spectrum Disorder Therapeutics Market was estimated to be valued at USD XX million in 2018 and is projected to reach USD XX million by 2026, at a CAGR of XX% during 2019 to 2026. Increasing R&D investment and increasing pediatric healthcare awareness are driving the market growth. However lack of skilled professionals might hamper the market growth.

The global autism spectrum disorder therapeutics market is primarily segmented based on treatment, age group and regions.

On the basis of treatment, the market is split into:
* Medication (Aripiprazole, Risperidone, Melatonin, Other Medications)
* Therapy (Anger Management, Family Therapy, Other Therapies)
* Other Treatments

On the basis of age group, the market is split into:
* Children
* Adult

Moreover, the market is classified based on region and countries as follows:
* North America- U.S., Canada
* Europe- U.K., France, Germany, Italy and Rest of Europe
* Asia-Pacific- China, Japan, India and Rest of Asia Pacific
* South America- Brazil, Mexico and Rest of South America
* Middle East & Africa- South Africa, Saudi Arabia and Rest of Middle East & Africa

Key Market Players:
The key players profiled in the market include:
* F. Hoffmann-La Roche AG
* Neurim Pharmaceuticals
* Yamo Pharmaceuticals
* Servier Laboratory
* Otsuka America Pharmaceutical, Inc.
* Curemark
* Oryzon Genomics
* GW Pharmaceuticals
* Pfizer Inc.
* Zynerba Pharmaceuticals

These enterprises are focusing on growth strategies, such as new product launches, expansions, acquisitions, and agreements & partnerships to expand their operations across the globe.

Key Benefits of the Report:
* Global, regional, country, treatment, age group and market size and their forecast from 2015-2026
* Identification and detailed analysis on key market dynamics, such as, drivers, restraints, opportunities, and challenges influencing growth of the market
* Detailed analysis on industry outlook with market specific PESTLE, and supply chain to better understand the market and build expansion strategies
* Identification of key market players and comprehensively analyze their market share and core competencies, detailed financial positions, key products, and unique selling points
* Analysis on key players’ strategic initiatives and competitive developments, such as joint ventures, mergers, and new product launches in the market
* Expert interviews and their insights on market shift, current and future outlook, and factors impacting vendors’ short term and long term strategies
* Detailed insights on emerging regions treatment, age group and options with qualitative and quantitative information and facts

Target Audience:
* Autism Spectrum Disorder Therapeutics Manufacturers and Providers
* Traders, Importers, and Exporters
* Raw Material Suppliers and Distributors
* Research and Consulting Firms
* Government and Research Organizations
* Associations and Industry Bodies

Research Methodology:
The market is derived through extensive use of secondary, primary, in-house research followed by expert validation and third party perspective, such as, analyst reports of investment banks. The secondary research is the primary base of our study wherein we conducted extensive data mining, referring to verified data sources, such as, white papers, government and regulatory published articles, technical journals, trade magazines, and paid data sources.

For forecasting, regional demand & supply factors, recent investments, market dynamics including technical growth scenario, consumer behavior, and end use trends and dynamics, and production capacity were taken into consideration. Different weightages have been assigned to these parameters and quantified their market impacts using the weighted average analysis to derive the market growth rate.

The market estimates and forecasts have been verified through exhaustive primary research with the Key Industry Participants (KIPs), which typically include:
* Manufacturers and Providers
* Suppliers
* Distributors
* Government Body & Associations
* Research Institutes

TABLE OF CONTENTS

1. Introduction

2. Research Methodology

3. Executive Summary

4. Global Autism Spectrum Disorder Therapeutics Market Overview
4.1. Market Segmentation & Scope
4.2. Market Trends
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Supply Chain Analysis
4.3. Global Autism Spectrum Disorder Therapeutics Market - Porter\'s Five Forces Analysis
4.4. Global Autism Spectrum Disorder Therapeutics Market - PESTEL Analysis

5. Global Autism Spectrum Disorder Therapeutics Market, by Treatment
5.1. Global Autism Spectrum Disorder Therapeutics Market, Size and Forecast, 2015-2026
5.2. Global Autism Spectrum Disorder Therapeutics Market by Medication, 2015-2026
5.2.1. Key driving factors, trends and opportunities
5.2.2. Market size and forecast, 2015-2026
5.2.3. Global Autism Spectrum Disorder Therapeutics Market by Aripiprazole, 2015-2026
5.2.3.1. Market size and forecast, 2015-2026
5.2.4. Global Autism Spectrum Disorder Therapeutics Market by Risperidone, 2015-2026
5.2.4.1. Market size and forecast, 2015-2026
5.2.5. Global Autism Spectrum Disorder Therapeutics Market by Melatonin, 2015-2026
5.2.5.1. Market size and forecast, 2015-2026
5.2.6. Global Autism Spectrum Disorder Therapeutics Market by Other Medications, 2015-2026
5.2.6.1. Market size and forecast, 2015-2026
5.3. Global Autism Spectrum Disorder Therapeutics Market by Therapy, 2015-2026
5.3.1. Key driving factors, trends and opportunities
5.3.2. Market size and forecast, 2015-2026
5.3.3. Global Autism Spectrum Disorder Therapeutics Market by Anger Management, 2015-2026
5.3.3.1. Market size and forecast, 2015-2026
5.3.4. Global Autism Spectrum Disorder Therapeutics Market by Family Therapy, 2015-2026
5.3.4.1. Market size and forecast, 2015-2026
5.3.5. Global Autism Spectrum Disorder Therapeutics Market by Other Therapies, 2015-2026
5.3.5.1. Market size and forecast, 2015-2026
5.4. Global Autism Spectrum Disorder Therapeutics Market by Other Treatments, 2015-2026
5.4.1. Key driving factors, trends and opportunities
5.4.2. Market size and forecast, 2015-2026

6. Global Autism Spectrum Disorder Therapeutics Market, by Age Group
6.1. Global Autism Spectrum Disorder Therapeutics Market, Size and Forecast, 2015-2026
6.2. Global Autism Spectrum Disorder Therapeutics Market by Children, 2015-2026
6.2.1. Key driving factors, trends and opportunities
6.2.2. Market size and forecast, 2015-2026
6.3. Global Autism Spectrum Disorder Therapeutics Market by Adult, 2015-2026
6.3.1. Key driving factors, trends and opportunities
6.3.2. Market size and forecast, 2015-2026

7. Global Autism Spectrum Disorder Therapeutics Market by Region
7.1. Autism Spectrum Disorder Therapeutics Market Regional Analysis, 2015-2026
7.2. Global Autism Spectrum Disorder Therapeutics Market Revenue (USD Million) by Region, 2015-2026
7.3. North America Autism Spectrum Disorder Therapeutics Market, 2015-2026
7.3.1. North America Autism Spectrum Disorder Therapeutics Market Size and Forecast, 2015-2026
7.3.2. North America Autism Spectrum Disorder Therapeutics Market by Country, 2015-2026
7.3.2.1. U.S. Autism Spectrum Disorder Therapeutics Market, 2015-2026
7.3.2.2. Canada Autism Spectrum Disorder Therapeutics Market, 2015-2026
7.4. Europe Autism Spectrum Disorder Therapeutics Market, 2015-2026
7.4.1. Europe Autism Spectrum Disorder Therapeutics Market Size and Forecast, 2015-2026
7.4.2. Europe Autism Spectrum Disorder Therapeutics Market by Country, 2015-2026
7.4.2.1. Germany Autism Spectrum Disorder Therapeutics Market, 2015-2026
7.4.2.2. France Autism Spectrum Disorder Therapeutics Market, 2015-2026
7.4.2.3. Italy Autism Spectrum Disorder Therapeutics Market, 2015-2026
7.4.2.4. UK Autism Spectrum Disorder Therapeutics Market, 2015-2026
7.4.2.5. Spain Autism Spectrum Disorder Therapeutics Market, 2015-2026
7.4.2.6. Rest of Europe Autism Spectrum Disorder Therapeutics Market, 2015-2026
7.5. Asia Pacific Autism Spectrum Disorder Therapeutics Market, 2015-2026
7.5.1. Asia Pacific Autism Spectrum Disorder Therapeutics Market Size and Forecast, 2015-2026
7.5.2. Asia Pacific Autism Spectrum Disorder Therapeutics Market by Country, 2015-2026
7.5.2.1. Japan Autism Spectrum Disorder Therapeutics Market, 2015-2026
7.5.2.2. China Autism Spectrum Disorder Therapeutics Market, 2015-2026
7.5.2.3. India Autism Spectrum Disorder Therapeutics Market, 2015-2026
7.5.2.4. Rest of Asia Pacific Autism Spectrum Disorder Therapeutics Market, 2015-2026
7.6. South America Autism Spectrum Disorder Therapeutics Market, 2015-2026
7.6.1. South America Autism Spectrum Disorder Therapeutics Market Size and Forecast, 2015-2026
7.6.2. South America Autism Spectrum Disorder Therapeutics Market by Country, 2015-2026
7.6.2.1. Mexico Autism Spectrum Disorder Therapeutics Market, 2015-2026
7.6.2.2. Brazil Autism Spectrum Disorder Therapeutics Market, 2015-2026
7.6.2.3. Rest of South America Autism Spectrum Disorder Therapeutics Market, 2015-2026
7.7. Middle East & Africa Autism Spectrum Disorder Therapeutics Market, 2015-2026
7.7.1. Middle East & Africa Autism Spectrum Disorder Therapeutics Market Size and Forecast, 2015-2026
7.7.2. Middle East & Africa Autism Spectrum Disorder Therapeutics Market by Country, 2015-2026
7.7.2.1. Saudi Arabia Autism Spectrum Disorder Therapeutics Market, 2015-2026
7.7.2.2. South Africa Autism Spectrum Disorder Therapeutics Market, 2015-2026
7.7.2.3. Rest of Middle East & Africa Autism Spectrum Disorder Therapeutics Market, 2015-2026

8. Competitive Landscape
8.1. Introduction
8.2. Market Share Analysis/Top Player Positioning, 2018

9. Company Profiles
9.1. F. Hoffmann-La Roche AG
9.1.1. Company Overview
9.1.2. Financial Overview
9.1.3. Product Benchmarking
9.1.4. Key Developments
9.2. Neurim Pharmaceuticals
9.2.1. Company Overview
9.2.2. Financial Overview
9.2.3. Product Benchmarking
9.2.4. Key Developments
9.3. Yamo Pharmaceuticals
9.3.1. Company Overview
9.3.2. Financial Overview
9.3.3. Product Benchmarking
9.3.4. Key Developments
9.4. Servier Laboratory
9.4.1. Company Overview
9.4.2. Financial Overview
9.4.3. Product Benchmarking
9.4.4. Key Developments
9.5. Otsuka America Pharmaceutical, Inc.
9.5.1. Company Overview
9.5.2. Financial Overview
9.5.3. Product Benchmarking
9.5.4. Key Developments
9.6. Curemark
9.6.1. Company Overview
9.6.2. Financial Overview
9.6.3. Product Benchmarking
9.6.4. Key Developments
9.7. Oryzon Genomics
9.7.1. Company Overview
9.7.2. Financial Overview
9.7.3. Product Benchmarking
9.7.4. Key Developments
9.8. GW Pharmaceuticals
9.8.1. Company Overview
9.8.2. Financial Overview
9.8.3. Product Benchmarking
9.8.4. Key Developments
9.9. Pfizer Inc.
9.9.1. Company Overview
9.9.2. Financial Overview
9.9.3. Product Benchmarking
9.9.4. Key Developments
9.10. Zynerba Pharmaceuticals
9.10.1. Company Overview
9.10.2. Financial Overview
9.10.3. Product Benchmarking
9.10.4. Key Developments

10. Key Insights

Content are not available

Choose License Type